MedSIR
Badalona, Massachusetts
What changed
Phase II trial registered: PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
2mo agoTrial registeredApr 29, 2026Source filing (opens the source filing in a new tab)
Momentum
Momentum 62 out of 100, unchanged since the last recompute.
Some recent activity, at a steady rate.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Phase II
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Trial
PHASE2 registered
Jul 22, 2024HER2-positive Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: MedSIR · PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
ClinicalTrials.gov · NCT06172127 (opens the source filing in a new tab)
- Trial
PHASE2 registered
May 2, 2017Breast Cancer Metastatic · COMPLETED · sponsor: MedSIR · Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients
ClinicalTrials.gov · NCT03328884 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources